A Huntington disease genetic test measures the number of CAG repeats in the HTT gene. Unlike standard sequencing, which looks for a change in individual DNA letters, this test evaluates the length and sometimes the sequence structure of a repeated region. The result can confirm Huntington disease in a person with compatible symptoms, predict future risk in an adult from an affected family, or support reproductive testing. Its meaning depends on the repeat range: 26 or fewer repeats is normal, 27–35 is intermediate, 36–39 has reduced penetrance, and 40 or more is considered a full-penetrance disease-causing expansion. Even a clearly positive result cannot state the exact age when symptoms will begin or how quickly they will progress. Because predictive testing can affect emotional health, family relationships, financial planning, and reproductive choices, testing should be voluntary and paired with specialized counseling rather than ordered as a routine blood test without preparation.
- The standard test counts CAG repeats in both copies of HTT and reports two allele sizes.
- A result of 40 or more repeats indicates a disease-causing expansion with very high lifetime penetrance.
- 36–39 repeats can cause Huntington disease but may remain asymptomatic throughout life.
- 27–35 repeats usually do not cause disease in the tested person but can be unstable when passed to a child.
- Repeat length influences average age at onset but cannot predict one person’s exact onset, symptoms, or course.
- Predictive testing of an adult without symptoms requires informed choice, counseling, and a plan for receiving the result.
Table of Contents
- What the HTT CAG Repeat Test Measures
- Who May Use Huntington Disease Genetic Testing
- HTT CAG Repeat Ranges and Their Meaning
- Technical Details That Can Change Interpretation
- The Predictive Testing Process
- Symptoms, Diagnosis, and Medical Care After Testing
- Family Inheritance and Reproductive Options
- Questions for the Testing Team
What the HTT CAG Repeat Test Measures
Huntington disease is caused by expansion of a CAG trinucleotide repeat in exon 1 of HTT. CAG is a three-letter DNA sequence that codes for the amino acid glutamine. When the repeat becomes sufficiently long, the resulting huntingtin protein contains an expanded polyglutamine tract and contributes to progressive dysfunction and loss of neurons.
Most people have two measurable HTT alleles, one inherited from each biological parent. A laboratory report may therefore list two numbers, such as 18 and 42 CAG repeats. In that example, the allele with 18 repeats is normal and the allele with 42 repeats is disease-causing. Huntington disease is inherited in an autosomal dominant manner, so one expanded allele is sufficient to create risk.
This is a specialized repeat expansion test. Ordinary exome sequencing, genome sequencing pipelines, or broad neurologic panels may not accurately size the HTT repeat unless they include a validated expansion assay. A person who needs Huntington disease testing should confirm that the laboratory directly measures the HTT CAG repeat and can detect alleles across the clinically relevant range.
What a repeat number can and cannot show
CAG length is the strongest known genetic contributor to age at onset. Larger disease-causing expansions are associated, on average, with earlier symptoms, and very large expansions are more often seen in juvenile-onset disease. However, people with the same repeat size can differ by many years in onset. Other genetic modifiers, somatic repeat expansion in tissues, health factors, and chance contribute to that variation.
The result cannot predict which symptom will appear first. Huntington disease may involve involuntary movement, impaired voluntary movement, changes in thinking and executive function, depression, irritability, apathy, compulsive behavior, sleep disturbance, or other psychiatric features. Repeat length also does not provide a reliable individual forecast of progression rate or life expectancy.
Why the family diagnosis should be verified
A family history described as “Huntington’s” may occasionally represent another movement disorder, inherited ataxia, dementia syndrome, medication effect, or acquired neurologic condition. When possible, testing should begin by confirming an HTT expansion in a relative with a clinical diagnosis. This prevents an unaffected relative from receiving a negative HTT result that falsely reassures the family when the original diagnosis was never molecularly established.
Who May Use Huntington Disease Genetic Testing
The same laboratory assay can be used in different clinical situations, but the preparation and interpretation are not identical.
Diagnostic testing for a person with symptoms
A neurologist may request HTT testing when a person has compatible motor, cognitive, or behavioral changes, particularly with a family history suggestive of autosomal dominant disease. A disease-causing expansion supports the diagnosis. A normal result makes classic HTT-related Huntington disease unlikely and may lead to evaluation for phenocopies, including other repeat expansion disorders, neurodegenerative diseases, metabolic conditions, structural brain disease, or medication-related movement disorders.
Genetic confirmation should be interpreted with a neurologic examination. A positive result in someone who has subtle or nonspecific complaints does not determine whether the person has reached clinical motor diagnosis. Conversely, a clinician should not dismiss important psychiatric or cognitive symptoms simply because obvious chorea is absent.
Predictive testing before symptoms
An adult who has a biological parent or other close relative with a confirmed HTT expansion may choose presymptomatic genetic testing. This is sometimes called predictive testing. The person is not seeking an explanation for current symptoms; they are deciding whether to learn if they inherited the family expansion.
Testing is optional. Some people want information for education, career, relationships, finances, caregiving, or reproductive planning. Others prefer uncertainty and exercise their right not to know. Neither choice is medically or morally superior. Family members, partners, employers, insurers, and clinicians should not coerce the decision.
Testing children and adolescents
Predictive testing is generally deferred until a person can make an informed adult decision because there is no childhood medical intervention that depends on knowing adult-onset status, and testing removes the future person’s choice not to know. This principle does not prohibit diagnostic evaluation of a child or adolescent who has concerning symptoms suggestive of juvenile Huntington disease. In that setting, testing addresses a current medical problem and should be coordinated by pediatric neurology and genetics specialists.
Prenatal and embryo testing
A known familial expansion can also be assessed through prenatal diagnosis or preimplantation genetic testing. These applications require advance planning, exact confirmation of the family allele, and counseling about what the repeat range means. They should not be treated as an extension of routine pregnancy carrier screening.
HTT CAG Repeat Ranges and Their Meaning
Clinical laboratories group HTT alleles into established ranges. The boundaries are important, but interpretation also depends on sequence structure, family context, and the reason for testing.
26 or fewer repeats: normal allele
An allele with 26 or fewer CAG repeats is considered normal and is stable enough that it is not expected to cause Huntington disease or expand into a disease-causing allele in the next generation. A person with two alleles in this range has not inherited an HTT expansion associated with Huntington disease.
For a truly at-risk relative, this is often called a negative predictive result. It means the person does not need Huntington-specific monitoring because of the family HTT expansion and cannot pass that expansion to children. It does not rule out unrelated neurologic or psychiatric conditions.
27–35 repeats: intermediate allele
An allele with 27–35 repeats is called intermediate. Most people with an intermediate allele do not develop Huntington disease. The major concern is reproductive instability: the repeat can change when transmitted and may expand into the disease-causing range in a child or later generation.
Expansion is more likely toward the upper end of the intermediate range and during paternal transmission, although an individual outcome cannot be guaranteed. A result in this range requires careful counseling because it is not a conventional “positive for Huntington disease” result, yet it may have implications for descendants. Rare sequence configurations can complicate interpretation near the upper boundary.
36–39 repeats: reduced-penetrance allele
An allele with 36–39 repeats is disease-causing but has reduced penetrance. Some carriers develop Huntington disease, often later in life, while others remain without recognized symptoms throughout a normal lifespan. The test cannot identify which outcome will occur for a specific person.
This range can be emotionally difficult because it does not produce the certainty people may expect from genetic testing. Age, neurologic findings, family history, repeat sequence, and evolving research may refine the discussion, but none can provide a guaranteed personal timeline. A person with a reduced-penetrance allele can transmit an allele that remains similar, contracts, or expands.
40 or more repeats: full-penetrance allele
An allele with 40 or more repeats is classified as a full-penetrance Huntington disease expansion. A person who lives to an advanced age is expected to develop manifestations, although the timing and presentation vary. Results in the low 40s are often associated with adult onset, while much larger expansions increase the likelihood of earlier onset.
The phrase “full penetrance” should not be mistaken for a precise prognosis. A 42-repeat result cannot specify whether symptoms will begin at age 35, 50, or another age, and it cannot predict the first symptom. Clinical diagnosis still depends on evaluation, not the DNA result alone.
Why reports may use slightly different wording
Laboratories may label ranges as normal, intermediate, reduced penetrance, and full penetrance; others may use terms such as mutable normal, uncertain significance, or pathogenic expansion. The repeat number and the laboratory’s explanatory notes are more informative than a single label. A genetics professional can translate the report into personal and family implications.
Technical Details That Can Change Interpretation
HTT testing is highly accurate when performed by an experienced laboratory, but repeat expansions have technical features that standard variant analysis does not address.
PCR sizing and very large alleles
Laboratories commonly use polymerase chain reaction and fragment analysis to size the repeat. An assay must be able to detect an expanded allele even when it amplifies less efficiently than the normal allele. Triplet-primed PCR or other confirmatory methods may be used to detect very large expansions and avoid apparent homozygosity when only the smaller allele is visible.
The report should provide repeat sizes and an analytic measurement range. Repeat sizing can vary by approximately one repeat between methods or laboratories, which matters most near category boundaries. Borderline findings may warrant confirmation or specialized sequence analysis.
CAA interruptions and loss-of-interruption variants
The typical HTT repeat region includes CAA interruptions that also encode glutamine but stabilize the DNA sequence. Some people have a loss-of-interruption, or LOI, configuration in which a CAA is replaced by CAG. Conventional assays may report the repeat count to the usual interruption and underestimate the uninterrupted CAG length by two repeats.
LOI variants are uncommon but enriched among some people with reduced-penetrance alleles and can be associated with earlier onset than the standard reported repeat number would suggest. They may also help explain rare symptomatic cases near an expected boundary. Not every laboratory routinely analyzes repeat interruptions, so this question is particularly relevant for unusual clinical–laboratory mismatches or results close to 36 repeats.
Somatic and germline instability
The repeat can change in different tissues over a lifetime, a process called somatic expansion. Blood testing measures the inherited repeat but not the full distribution that may develop in brain cells. Research increasingly links somatic instability to disease timing, but it is not yet a routine clinical prognostic test.
The repeat can also change during egg or sperm formation. Expansion is more common with paternal transmission, and large expansions associated with juvenile disease are most often inherited from the father. Anticipation describes the tendency for a larger repeat and earlier onset in a later generation, but it is a family-level pattern, not a certainty for every pregnancy.
A VUS is uncommon in standard repeat reporting
Unlike sequencing panels, HTT CAG testing usually reports a measured repeat category rather than a typical single-letter variant of uncertain significance. Uncertainty can still arise at reduced-penetrance sizes, from unusual repeat structures, or when symptoms do not match the result. Additional sequencing or testing for another disorder may be appropriate, but an ordinary HTT sequencing VUS should not be assumed to cause Huntington disease.
The Predictive Testing Process
The laboratory step is simple; the decision is not. A well-designed predictive program helps the person make an informed, voluntary choice and prepares for either result.
Before the blood draw
Pretest counseling reviews the pedigree, verifies the family diagnosis, explains all repeat ranges, and explores why the person wants testing now. It should discuss possible effects on mood, relationships, employment, insurance, privacy, caregiving expectations, and reproductive plans. Legal protections vary by country and may not cover life, disability, or long-term-care insurance, so jurisdiction-specific advice may be important before testing.
The team should assess current mental health, coping strategies, support, and safety. Depression or anxiety does not automatically prevent testing, but an acute crisis may need stabilization first. The person may identify a support person while preserving the right to receive the result privately.
A baseline neurologic evaluation is often offered. Some adults decline an examination because they want only gene status; programs should explain the implications and use a process that respects autonomy while maintaining safety.
Receiving the result
Results should be disclosed in a planned setting by a clinician familiar with Huntington disease. The person should know when, how, and with whom the result will be delivered. Abrupt release through an electronic portal without context can cause avoidable harm, particularly if the report includes an intermediate or reduced-penetrance result.
A negative result may bring relief but can also cause guilt, altered family identity, or difficulty reconnecting with relatives who remain at risk. A positive result may cause grief, anger, urgency, or temporary numbness even when the person expected it. Follow-up should be offered for every result category, not only a full-penetrance expansion.
When the person changes their mind
Consent is a process. An adult can postpone or stop predictive testing before learning the result. Once the result has been disclosed, the knowledge cannot be reversed, so programs should avoid rushing because of family pressure, pregnancy planning, or an upcoming life event. Reproductive planning can often begin with counseling before the person decides whether to learn their own status.
Symptoms, Diagnosis, and Medical Care After Testing
A gene-positive adult without diagnostic symptoms does not automatically need treatment for Huntington disease. Follow-up can be individualized through a Huntington disease or movement-disorders clinic, with attention to emotional health, general health, advance planning, and research opportunities.
Clinical diagnosis is broader than chorea
Huntington disease can affect movement, cognition, behavior, and psychiatric health. Early changes may include reduced coordination, impaired planning, irritability, depression, apathy, or subtle motor findings. Chorea is common but not required as the first manifestation. Juvenile presentations more often include rigidity, slowness, dystonia, school decline, and sometimes seizures rather than prominent chorea.
A neurologist determines whether symptoms are attributable to Huntington disease and whether diagnostic motor criteria are met. The CAG result informs that assessment but does not replace it.
Care after symptoms begin
Management is multidisciplinary and symptom-focused. Depending on need, care may include medications for chorea or psychiatric symptoms, physical and occupational therapy, speech and swallowing assessment, nutrition support, cognitive and behavioral strategies, social work, driving review, and advance-care planning. Treatment choices depend on the person’s symptoms and comorbidities rather than repeat number alone.
Clinical research is active, including studies of huntingtin-lowering approaches and modifiers of repeat instability. A positive result does not guarantee eligibility for a trial, and experimental interventions should be discussed through reputable centers.
Mental-health safety
Depression, impulsivity, and suicidal thinking can occur in people at risk, during testing, and after diagnosis. New suicidal thoughts, intent, inability to stay safe, severe agitation, or psychosis require urgent local crisis or emergency assessment. Testing programs should provide a concrete contact plan rather than assuming the person will request help during distress.
Family Inheritance and Reproductive Options
A person with an expanded HTT allele has a 50% chance of transmitting that allele in each pregnancy. The probability is the same for sons and daughters and is recalculated independently for every pregnancy. The child’s exact repeat size may differ because of germline instability.
What a result means for relatives
A full-penetrance or reduced-penetrance expansion may indicate that siblings, adult children, and other biological relatives are at risk. The tested person controls disclosure of their medical information, but genetic counseling can help plan a respectful family letter that explains how relatives can access testing.
A negative predictive result in a person whose parent has a confirmed expansion means that person did not inherit it and cannot pass it on. Their children are not at increased HTT-related risk through them. An intermediate allele requires a different conversation because the tested person is usually not expected to develop Huntington disease, yet transmission instability may create risk in descendants.
Reproductive choices
Options may include natural conception without testing, prenatal diagnosis through chorionic villus sampling or amniocentesis, use of donor eggs or sperm, adoption, or in vitro fertilization with preimplantation genetic testing for monogenic disease. PGT-M tests embryos for the family HTT haplotype or expansion before transfer, but IVF has medical, emotional, financial, and technical limitations.
Some programs offer exclusion or nondisclosure strategies for a person who does not want to learn their own status. These approaches can reduce the chance of an affected pregnancy while attempting to preserve the at-risk adult’s uncertainty, but they are ethically and technically complex and not available everywhere. Early consultation with reproductive genetics and an experienced IVF laboratory is essential.
Prenatal testing can indirectly reveal a parent’s status, especially when the parent has not had predictive testing. The family should decide before pregnancy what results they are willing to receive and how they would use them. Testing a pregnancy without a clear plan for possible outcomes can create severe time pressure and conflict.
Questions for the Testing Team
Before testing, ask questions that address both laboratory quality and the personal consequences of learning the result:
- Has Huntington disease been genetically confirmed in an affected relative?
- Is this diagnostic testing for current symptoms or predictive testing before symptoms?
- Will the laboratory report both HTT allele sizes and detect very large expansions?
- How does the laboratory handle results near 35–40 repeats and possible measurement variation?
- Can it evaluate CAA interruptions or loss-of-interruption variants when clinically indicated?
- What support is available before disclosure and in the days and months afterward?
- How will the result be protected from automatic portal release or unintended family access?
- What insurance, employment, and privacy rules apply where I live?
- Would a baseline neurologic or mental-health assessment be useful before testing?
- Which relatives could benefit from counseling, and who should not be tested yet?
- What reproductive options are available if I do or do not want to learn my own status?
- Who should I contact urgently if testing causes severe distress or safety concerns?
The most useful report is one that gives exact repeat counts, explains the laboratory method and limitations, and connects the range to penetrance without overpromising prognosis. The most responsible testing process is one that protects voluntary choice and continues after the result is delivered.
References
- Caron NS, Wright GEB, Hayden MR. Huntington Disease. GeneReviews®, updated 2025. Expert clinical review.
- Pengo M, et al. The Multifaceted Role of Genetics in Huntington Disease. International Journal of Molecular Sciences, 2024. Scientific review.
- Dawson J, et al. The Frequency and Clinical Impact of Synonymous HTT Loss-of-Interruption Variants. Journal of Medical Genetics, 2024. Cohort study.
- Scahill RI, et al. Somatic CAG Repeat Expansion in Blood Associates With Huntington’s Disease Onset and Progression. Cell, 2025. Longitudinal research study.
- Stoker TB, Mason SL, Greenland JC, Holden ST, Santini H, Barker RA. Huntington’s Disease: Diagnosis and Management. Practical Neurology, 2022. Clinical review.
- Nance MA, Bird TD. Genetic Counseling and Testing for Huntington’s Disease. Handbook of Clinical Neurology, 2017. Expert review.
Disclaimer
This article provides general education and is not a substitute for individualized neurologic care, genetic counseling, mental-health assessment, or legal advice. Predictive Huntington disease testing should be voluntary and coordinated by professionals experienced with HTT repeat results. Anyone with suicidal thoughts, intent, or inability to remain safe should seek immediate local emergency or crisis support.
